Estimated average glucose (eAG) from HbA1c is a practical way to translate your glycated haemoglobin result into the familiar mmol/L units seen on home glucose monitors. HbA1c reflects average blood glucose over the preceding two to three months, making it a cornerstone of diabetes diagnosis and management across the NHS. Converting this figure into an eAG can help patients understand what their laboratory result means in everyday terms. This article explains how eAG is calculated, what the reference ranges mean, how NICE and the NHS use HbA1c in clinical practice, and when to seek advice from your GP or diabetes team.

What Is HbA1c and Why It Matters for Diabetes Management

HbA1c measures the proportion of glycated haemoglobin to reflect average blood glucose over two to three months, and is the primary test used for diagnosing and monitoring diabetes in UK adults, though it is not suitable in all clinical situations.

HbA1c — formally known as glycated haemoglobin — is a blood test that reflects your average blood glucose levels over the preceding two to three months. When glucose circulates in the bloodstream, it binds irreversibly to haemoglobin, the protein found inside red blood cells. Because red blood cells have a lifespan of approximately 120 days (though this varies between individuals), the proportion of haemoglobin that has become glycated provides a reliable snapshot of longer-term glucose control, rather than a single moment in time.

In the UK, HbA1c is widely used in the diagnosis and ongoing management of type 2 diabetes in adults, and for monitoring glucose control in people with established diabetes. However, it is important to note that HbA1c is not recommended as a diagnostic tool in certain situations, including:

• Suspected type 1 diabetes

• Children and young people

• Pregnancy

• Acute presentations or recent onset of symptoms suggesting diabetes

• Conditions that affect red blood cell turnover or haemoglobin structure (see Limitations section)

In these circumstances, plasma glucose measurements are used instead. If you are unsure which test applies to your situation, your GP or diabetes team can advise.

HbA1c is measured in millimoles per mole (mmol/mol) in the UK, following IFCC (International Federation of Clinical Chemistry) standardisation, though older literature may still reference percentage values. Unlike a fasting glucose test or a finger-prick reading — which can fluctuate significantly depending on recent meals, physical activity, or stress — HbA1c smooths out these day-to-day variations.

For people living with type 1 or type 2 diabetes, regular HbA1c monitoring — typically every three to six months — helps clinicians and patients assess whether blood glucose is being managed effectively. Persistently elevated HbA1c is associated with an increased risk of long-term complications, including diabetic retinopathy, nephropathy, neuropathy, and cardiovascular disease. Understanding what your HbA1c means in practical, everyday terms — such as an estimated average glucose (eAG) figure — can make the result feel more tangible and actionable.

How Estimated Average Glucose Is Calculated from HbA1c

eAG is calculated using the ADAG formula — eAG (mmol/L) ≈ (1.5944 × HbA1c in %) − 2.5944 — converting HbA1c into mmol/L units familiar from home glucose monitoring, though it is a population-derived estimate rather than a precise individual measurement.

The estimated average glucose (eAG) is a derived figure that translates your HbA1c result into units more familiar from day-to-day blood glucose monitoring — millimoles per litre (mmol/L) in the UK. The concept was developed to bridge the gap between laboratory HbA1c values and the glucose readings patients see on their home glucometers or continuous glucose monitors (CGMs).

The calculation is based on a validated mathematical formula derived from the ADAG (A1c-Derived Average Glucose) study, published in the New England Journal of Medicine in 2008, which correlated HbA1c values with average glucose readings obtained from continuous monitoring across a diverse population. The widely used formula is:

eAG (mmol/L) ≈ (1.5944 × HbA1c in %) − 2.5944

Using this formula, approximate eAG values for common HbA1c results are:

• An HbA1c of 48 mmol/mol (6.5%) corresponds to an eAG of approximately 7.8 mmol/L

• An HbA1c of 58 mmol/mol (7.5%) corresponds to an eAG of approximately 9.3 mmol/L

• An HbA1c of 75 mmol/mol (9.0%) corresponds to an eAG of approximately 11.7 mmol/L

It is worth noting that UK laboratories typically report HbA1c in mmol/mol and do not routinely include an eAG figure on their reports. Diabetes UK provides an HbA1c converter tool on its website that allows patients to calculate an approximate eAG from their result; however, eAG is an educational aid and is not currently used as a formal decision-making metric within NICE clinical guidelines.

It is important to understand that eAG is a statistical estimate — a population-derived average — rather than a precise measurement of your individual glucose levels at any given point. It does not replace self-monitoring of blood glucose but serves as a useful educational and motivational tool to contextualise HbA1c results in terms patients can more readily relate to.

Understanding Your Results: HbA1c and Average Glucose Ranges

In UK practice, an HbA1c below 42 mmol/mol is normal, 42–47 mmol/mol indicates non-diabetic hyperglycaemia (prediabetes), and 48 mmol/mol or above is diagnostic of diabetes, corresponding to eAG values of approximately 7.0, 7.0–7.6, and 7.8 mmol/L respectively.

Interpreting your HbA1c and its corresponding estimated average glucose requires an understanding of the reference ranges used in UK clinical practice. The following categories are broadly recognised:

For diagnosis and screening (adults without conditions affecting HbA1c reliability):

• Below 42 mmol/mol (6.0%): Normal range — diabetes is unlikely; eAG approximately 7.0 mmol/L or below

• 42–47 mmol/mol (6.0–6.4%): Non-diabetic hyperglycaemia (prediabetes) — increased risk of developing type 2 diabetes; eAG approximately 7.0–7.6 mmol/L

• 48 mmol/mol (6.5%) or above: Indicative of diabetes — eAG approximately 7.8 mmol/L or above

If you do not have symptoms of diabetes, a diagnosis based on HbA1c requires confirmation on a second test on a separate occasion. A single raised result is not sufficient to diagnose diabetes in the absence of symptoms. As noted above, HbA1c should not be used for diagnosis in pregnancy, children, suspected type 1 diabetes, or where conditions affecting red blood cell turnover are present.

For people already diagnosed with diabetes, NICE guidelines recommend individualised HbA1c targets rather than a one-size-fits-all approach. General targets, as outlined in NICE NG17 and NG28, include:

• 48 mmol/mol (6.5%) for people with type 2 diabetes managed by lifestyle or a single non-hypoglycaemic agent (NICE NG28)

• 53 mmol/mol (7.0%) for those on medications that carry a hypoglycaemia risk, such as sulphonylureas or insulin (NICE NG28)

• 48 mmol/mol (6.5%) or below for adults with type 1 diabetes, where this can be achieved safely without problematic hypoglycaemia (NICE NG17)

Targets may be adjusted for older adults, those with significant comorbidities, or individuals with a history of severe hypoglycaemia. Always discuss what your personal target should be with your GP or diabetes care team.

How the NHS and NICE Use HbA1c to Guide Diabetes Care

NICE NG17 and NG28 embed HbA1c testing every three to six months into NHS diabetes pathways, using results to guide treatment intensification, medication choice, and referral to the NHS Diabetes Prevention Programme for those with prediabetes.

In the UK, HbA1c testing is embedded throughout NHS diabetes pathways, from initial diagnosis through to long-term complication prevention. The key NICE guidelines are NG17 (type 1 diabetes in adults: diagnosis and management) and NG28 (type 2 diabetes in adults: management), which outline how HbA1c should be used to inform treatment decisions, medication adjustments, and referral pathways.

For people with type 2 diabetes, NICE NG28 recommends that HbA1c is measured every three to six months when treatment is being adjusted, and every six months once stable. If HbA1c rises above an agreed threshold despite optimised lifestyle measures, clinicians are guided to consider intensifying treatment. The choice of additional therapy depends on a range of individual factors — including the presence of cardiovascular disease or chronic kidney disease, hypoglycaemia risk, body weight, and patient preference — and is not a simple stepwise progression. For example, SGLT2 inhibitors or GLP-1 receptor agonists may be considered in specific clinical circumstances, such as established cardiovascular disease or significant obesity, rather than as routine second-line options for all patients. Your diabetes team will discuss the most appropriate options for your individual situation.

The NHS Diabetes Prevention Programme (NHS DPP) also uses HbA1c as a key eligibility criterion. Individuals identified with non-diabetic hyperglycaemia (42–47 mmol/mol) are referred to structured lifestyle intervention programmes designed to reduce the risk of progression to type 2 diabetes, in line with the NHS Long Term Plan's commitment to prevention.

Estimated average glucose figures are not formally embedded in NICE clinical guidelines as a decision-making tool. However, they are increasingly used as an educational aid in patient consultations, helping patients understand the real-world implications of their HbA1c results and the potential impact of lifestyle or medication changes.

Limitations of Estimated Average Glucose Figures

eAG is a population average that may not reflect individual glucose levels accurately, and is unreliable when conditions such as haemolytic anaemia, haemoglobinopathies, iron deficiency, or pregnancy alter red blood cell turnover or haemoglobin structure.

Whilst the estimated average glucose derived from HbA1c is a useful educational tool, it carries several important limitations that both patients and clinicians should be aware of.

Firstly, eAG is a population average, not an individual measurement. The ADAG formula was derived from a study population and may not accurately reflect the average glucose of every individual. There is recognised inter-individual variability in the relationship between HbA1c and average glucose, related to differences in red blood cell lifespan and glycation rates. Some people tend to have HbA1c values that run higher relative to their actual average glucose, whilst others tend to run lower. This means that two people with the same HbA1c may have meaningfully different true average glucose levels.

Secondly, certain medical conditions and other factors can distort HbA1c results, making the eAG calculation unreliable:

• Haemolytic anaemia or haemoglobinopathies (such as sickle cell disease or thalassaemia) reduce red blood cell lifespan, leading to falsely low HbA1c values

• Iron deficiency anaemia can falsely elevate HbA1c

• Recent blood transfusion, erythropoietin (EPO) therapy, or acute blood loss alter red cell populations and can distort results

• Certain haemoglobin variants may interfere with some HbA1c assay methods

• Severe chronic kidney disease and associated anaemia can affect HbA1c reliability

• Certain medicines, including dapsone, may cause haemolysis and affect results

• Pregnancy alters red blood cell turnover, making HbA1c less reliable — alternative monitoring methods are recommended (NICE NG3)

Where HbA1c is unreliable, your clinical team will use plasma glucose measurements instead.

Thirdly, eAG does not capture glucose variability. A person who experiences frequent hypoglycaemic episodes followed by rebound hyperglycaemia may have the same HbA1c — and therefore the same eAG — as someone with consistently stable glucose levels. This is a significant limitation, particularly for people with type 1 diabetes, where glucose variability is a major clinical concern. In such cases, time-in-range data from continuous glucose monitoring provides a more complete picture than HbA1c or eAG alone.

When to Speak to Your GP or Diabetes Team About Your Levels

Seek emergency help immediately for symptoms of DKA or HHS; contact your GP promptly if your HbA1c has risen above your agreed target, you have frequent hypoglycaemia, or you are pregnant or planning a pregnancy.

Knowing when to seek professional advice about your HbA1c or estimated average glucose is an important aspect of safe self-management. Whilst routine monitoring is typically arranged through your GP surgery or diabetes clinic, there are specific circumstances in which you should seek advice promptly rather than waiting for your next scheduled appointment.

Seek emergency help immediately (call 999 or go to your nearest A&E) if you or someone else develops symptoms that may suggest a hyperglycaemic emergency such as diabetic ketoacidosis (DKA) or hyperosmolar hyperglycaemic state (HHS). Warning signs include:

• Vomiting, severe abdominal pain, or rapid deep breathing

• Confusion, marked drowsiness, or loss of consciousness

• Very high blood glucose readings, particularly with ketones present

These are medical emergencies and require immediate assessment.

Contact your GP or diabetes team promptly if:

• Your HbA1c result has risen significantly since your last test, particularly if it has moved above your agreed target

• You are experiencing symptoms that may suggest poorly controlled blood glucose, such as increased thirst, frequent urination, unexplained fatigue, blurred vision, or recurrent infections

• You are having frequent episodes of hypoglycaemia (low blood sugar), which may indicate that your medication dose needs reviewing

• You are pregnant or planning a pregnancy — tighter glucose control is essential both before and during pregnancy. NICE NG3 recommends aiming for an HbA1c below 48 mmol/mol (6.5%) before conception if this can be achieved safely. If your HbA1c is above 86 mmol/mol (10%), specialist review and effective contraception are strongly advised before attempting pregnancy, as the risks to mother and baby are significantly increased at this level

• You have been diagnosed with a condition that may affect the reliability of your HbA1c, such as anaemia or a haemoglobinopathy

If your HbA1c is in the non-diabetic hyperglycaemia range (42–47 mmol/mol), your GP should discuss lifestyle modifications with you and may refer you to the NHS Diabetes Prevention Programme. This is not a cause for alarm, but it is an important opportunity to make changes that can significantly reduce your risk of developing type 2 diabetes.

If you experience a suspected side effect from any diabetes medication — including severe hypoglycaemia — you can report this to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. Your healthcare team can also help you report or manage any concerns about your medicines.

Experiencing these side effects? Our pharmacists can help you navigate them →

For those already managing diabetes, remember that HbA1c and eAG are tools to support — not replace — the broader conversation with your healthcare team. Bring your results, your home glucose readings, and any concerns to your appointments. Shared decision-making, informed by accurate data, leads to better outcomes.

Frequently Asked Questions